Patents by Inventor Etsuko Hirose

Etsuko Hirose has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12287160
    Abstract: An aluminum fin material includes an aluminum plate, an erosion-resistant coating layer on a surface of the aluminum plate, and a hydrophilic coating layer formed on a surface of the erosion-resistant coating layer. The erosion-resistant coating layer contains an acrylic resin and fluororesin particles, an amount of the erosion-resistant coating layer is 0.05 mg/dm2 or more and 8.00 mg/dm2 or less, and a content of the fluororesin particles in the erosion-resistant coating layer is 0.05 mass % or more and 8.00 mass % or less.
    Type: Grant
    Filed: January 25, 2021
    Date of Patent: April 29, 2025
    Assignees: Kobe Steel, Ltd., Mitsubishi Electric Corporation
    Inventors: Ryosuke Tsunoda, Keita Tateyama, Reiji Morioka, Etsuko Hirose, Yoshinori Yamamoto
  • Patent number: 8592428
    Abstract: The present invention relates to compounds, which are useful for treatment and/or prevention of diabetes mellitus, diabetes mellitus complications or obesity, since the compounds have glucokinase-activating effects, and are presented in Formula (I): wherein R1 represents a lower alkylsulfonyl group; R2 represents a hydrogen atom; R20 represents, e.g., a hydrogen atom; m represents an integer of from 1 to 3; and n represents zero or 1, or relates to a pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: August 3, 2009
    Date of Patent: November 26, 2013
    Assignee: MSD K. K.
    Inventors: Hideaki Imamura, Takuya Suga, Hiroyuki Takahashi, Hideki Jona, Etsuko Hirose, Norikazu Ohtake
  • Publication number: 20120108817
    Abstract: The present invention relates to compounds, which are useful for treatment and/or prevention of diabetes mellitus, diabetes mellitus complications or obesity, since the compounds have glucokinase-activating effects, and are presented in Formula (I): wherein R1 represents a lower alkylsulfonyl group; R2 represents a hydrogen atom; R20 represents, e.g., a hydrogen atom; m represents an integer of from 1 to 3; and n represents zero or 1, or relates to a pharmaceutically acceptable salts thereof.
    Type: Application
    Filed: August 3, 2009
    Publication date: May 3, 2012
    Inventors: Hideaki Imamura, Takuya Suga, Hiroyuki Takahashi, Hideki Jona, Etsuko Hirose, Norikazu Ohtake
  • Publication number: 20100324049
    Abstract: [Problems] To provide an antagonist of a melanin-concentrating hormone receptor, which is useful as a medicine for a central nervous system disease, a cardiovascular disease or a metabolic disease. [Means for Solving Problems] The antagonist comprises, as an active ingredient, a compound represented by the formula (I) wherein R1a and R1b independently represent a hydrogen atom or a C1-6 alkyl group; R2a, R2b, R3a and R3b independently represent a hydrogen atom, a C1-6 alkyl group, or the like; Y represents H or —OH; Z represents —OR8, or the like; R8 represents a hydrogen atom, a C1-6 alkyl group which may have a substituent, or the like; R9a and R9b independently represent a hydrogen atom, a C1-6 alkyl group, or the like; Ar1 represents an aromatic carbon ring group, or an aromatic heteroring group; Ar2 represents a group produced by removing two hydrogen atoms from an aromatic carbon ring, or the like; and the ring group A represents an unsaturated heteroring group.
    Type: Application
    Filed: September 26, 2008
    Publication date: December 23, 2010
    Inventors: Makoto Ando, Minoru Kameda, Hiroshi Miyazoe, Minoru Moriya, Etsuko Hirose, Takao Suzuki